-
2
-
-
80053289254
-
The evolution of antiplatelet therapy in cardiovascular disease
-
Yousuf O, Bhatt DL. The evolution of antiplatelet therapy in cardiovascular disease. Nature Rev Cardiol 2011; 8: 547-559.
-
(2011)
Nature Rev Cardiol
, vol.8
, pp. 547-559
-
-
Yousuf, O.1
Bhatt, D.L.2
-
3
-
-
75949128633
-
Antiplatelet therapies for the treatment of cardiovascular disease
-
Michelson AD. Antiplatelet therapies for the treatment of cardiovascular disease. Nat Rev Drug Disc 2010; 9: 154-169.
-
(2010)
Nat Rev Drug Disc
, vol.9
, pp. 154-169
-
-
Michelson, A.D.1
-
4
-
-
84859085011
-
Progress for stroke prevention with atrial fibrillation. Emergence of novel oral anticoagulants
-
Katsnelson M, Sacco RL, Moscucci M. Progress for stroke prevention with atrial fibrillation. Emergence of novel oral anticoagulants. Circulation 2012; 125: 1577-1583.
-
(2012)
Circulation
, vol.125
, pp. 1577-1583
-
-
Katsnelson, M.1
Sacco, R.L.2
Moscucci, M.3
-
5
-
-
70450187946
-
Cangrelor: A review on its mechanism of action and clinical development
-
Ferreiro JL, Ueno M, Angiolillo DJ. Cangrelor: a review on its mechanism of action and clinical development. Expert Rev Cardiovasc Ther 2009; 7: 1195-1201.
-
(2009)
Expert Rev Cardiovasc Ther
, vol.7
, pp. 1195-1201
-
-
Ferreiro, J.L.1
Ueno, M.2
Angiolillo, D.J.3
-
6
-
-
71849119604
-
Intravenous platelet blockade with cangrelor during PCI
-
CHAMPION PLATFORM Investigators
-
Bhatt DL, Lincoff AM, Gibson CM, et al; CHAMPION PLATFORM Investigators. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med 2009; 361: 2330-2341.
-
(2009)
N Engl J Med
, vol.361
, pp. 2330-2341
-
-
Bhatt, D.L.1
Lincoff, A.M.2
Gibson, C.M.3
-
7
-
-
71849087338
-
Platelet inhibition with cangrelor in patients undergoing PCI
-
Harrington RA, Stone GW, McNulty S, et al. Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med 2009; 361: 2318-2329.
-
(2009)
N Engl J Med
, vol.361
, pp. 2318-2329
-
-
Harrington, R.A.1
Stone, G.W.2
McNulty, S.3
-
8
-
-
84856023997
-
Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: A randomized controlled trial
-
BRIDGE Investigators
-
Angiolillo DJ, Firstenberg MS, Price MJ, et al., BRIDGE Investigators. Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. J Am Med Assoc 2012; 307: 265-274.
-
(2012)
J Am Med Assoc
, vol.307
, pp. 265-274
-
-
Angiolillo, D.J.1
Firstenberg, M.S.2
Price, M.J.3
-
9
-
-
77955677366
-
Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y(12)-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI)
-
Leonardi S, Rao SV, Harrington RA, et al. Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y(12)-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI). Am Heart J 2010; 160: 65-72.
-
(2010)
Am Heart J
, vol.160
, pp. 65-72
-
-
Leonardi, S.1
Rao, S.V.2
Harrington, R.A.3
-
10
-
-
73149118496
-
The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP2C19*2 genotype: First experience in patients
-
Gurbel PA, Bliden KP, Antonino MJ, et al. The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP2C19*2 genotype: first experience in patients. J Thromb Haemost 2010: 8: 43-53.
-
(2010)
J Thromb Haemost
, vol.8
, pp. 43-53
-
-
Gurbel, P.A.1
Bliden, K.P.2
Antonino, M.J.3
-
11
-
-
84864617340
-
A randomized double-blind active-controlled phase II trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: The INNOVATE-PCI trial
-
INNOVATE-PCI Investigators
-
Welsh RC, Rao SV, Zeymer U, et al., INNOVATE-PCI Investigators. A randomized double-blind active-controlled phase II trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PCI trial. Circ Cardiovasc Intervention 2012, 5: 336-346.
-
(2012)
Circ Cardiovasc Intervention
, vol.5
, pp. 336-346
-
-
Welsh, R.C.1
Rao, S.V.2
Zeymer, U.3
-
12
-
-
18044388905
-
Preclinical and clinical studies with selective reversible direct P2Y12 antagonists
-
van Giezen JJJ, Humphries RG. Preclinical and clinical studies with selective reversible direct P2Y12 antagonists. Semin Thromb Hemost 2005; 31: 195-204.
-
(2005)
Semin Thromb Hemost
, vol.31
, pp. 195-204
-
-
van Giezen, J.J.J.1
Humphries, R.G.2
-
13
-
-
34248371253
-
Clinical aspects of platelet inhibitors and thrombus formation
-
Meadows TA, Bhatt DL. Clinical aspects of platelet inhibitors and thrombus formation. Circ Res 2007; 100: 1261-1275.
-
(2007)
Circ Res
, vol.100
, pp. 1261-1275
-
-
Meadows, T.A.1
Bhatt, D.L.2
-
14
-
-
58649088469
-
Protease-activated receptors in cardiovascular health and disease
-
Shah R. Protease-activated receptors in cardiovascular health and disease. Am Heart J 2009; 157: 253-262.
-
(2009)
Am Heart J
, vol.157
, pp. 253-262
-
-
Shah, R.1
-
15
-
-
78149281431
-
SCH 602539, a protease-activated receptor-1 antagonist, inhibits thrombosis alone and in combination with cangrelor in a Folts model of arterial thrombosis in cynomolgus monkeys
-
Chintala M, Strony J, Yang B, et al., SCH 602539, a protease-activated receptor-1 antagonist, inhibits thrombosis alone and in combination with cangrelor in a Folts model of arterial thrombosis in cynomolgus monkeys. Arterioscler Thromb Vasc Biol 2010; 30: 2143-2149.
-
(2010)
Arterioscler Thromb Vasc Biol
, vol.30
, pp. 2143-2149
-
-
Chintala, M.1
Strony, J.2
Yang, B.3
-
16
-
-
44949114152
-
Discovery of a novel orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity
-
Chackalamannil S, Wang Y, Greenlee WJ, et al. Discovery of a novel orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity. J Med Chem 2008; 51: 3061-3064.
-
(2008)
J Med Chem
, vol.51
, pp. 3061-3064
-
-
Chackalamannil, S.1
Wang, Y.2
Greenlee, W.J.3
-
17
-
-
84871411930
-
High-resolution crystal structure of human protease-activated receptor 1
-
Zhang C, Srinivasan Y, Arlow DH, et al. High-resolution crystal structure of human protease-activated receptor 1. Nature 2012; 492: 387-392.
-
(2012)
Nature
, vol.492
, pp. 387-392
-
-
Zhang, C.1
Srinivasan, Y.2
Arlow, D.H.3
-
18
-
-
61849180442
-
Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: A randomized, double-blind, placebo-controlled study
-
Becker RC, Moliterno DJ, Jennings LK, et al. Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomized, double-blind, placebo-controlled study. Lancet 2009; 373: 919-928.
-
(2009)
Lancet
, vol.373
, pp. 919-928
-
-
Becker, R.C.1
Moliterno, D.J.2
Jennings, L.K.3
-
19
-
-
83655177669
-
Thrombin-receptor antagonist voraxapar in acute coronary syndromes
-
for the TRACER investigators
-
Tricoci P, Huang Z, Held C, et al., for the TRACER investigators. Thrombin-receptor antagonist voraxapar in acute coronary syndromes. N Engl J Med 2012; 12: 366: 20-33.
-
(2012)
N Engl J Med
, vol.12
, Issue.366
, pp. 20-33
-
-
Tricoci, P.1
Huang, Z.2
Held, C.3
-
20
-
-
84859555815
-
Voraxapar in the secondary prevention of atherothrombotic events
-
for the TRA2P-TIMI 50 steering committee and investigators
-
Morrow DA, Braunwald E, Bonaca MP, et al., for the TRA2P-TIMI 50 steering committee and investigators. Voraxapar in the secondary prevention of atherothrombotic events. N Engl J Med 2012; 366: 1404-1413.
-
(2012)
N Engl J Med
, vol.366
, pp. 1404-1413
-
-
Morrow, D.A.1
Braunwald, E.2
Bonaca, M.P.3
-
21
-
-
84867336413
-
Voraxapar for secondary prevention of thrombotic events for patients with previous myocardial infarction: A prespecified subgroup analysis of the TRA2P-TIMI 50 trial
-
for the TRA2P-TIMI 50 steering committee investigators
-
Scirica BM, Bonaca MP, Braunwald E, et al., for the TRA2P-TIMI 50 steering committee investigators. Voraxapar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA2P-TIMI 50 trial. Lancet 2012; 380: 1317-1324.
-
(2012)
Lancet
, vol.380
, pp. 1317-1324
-
-
Scirica, B.M.1
Bonaca, M.P.2
Braunwald, E.3
-
22
-
-
84886996869
-
Effects of E5555, on inflammatory markers in vivo
-
abstract P-M-059
-
Kogushi M, Yokohama H, Kitamura S, et al. Effects of E5555, on inflammatory markers in vivo. J Thromb Haemost 2007; 5: Abstract P-M-059.
-
(2007)
J Thromb Haemost
, vol.5
-
-
Kogushi, M.1
Yokohama, H.2
Kitamura, S.3
-
23
-
-
79955618078
-
Inhibitors of the platelet thrombin receptor. Will they live up to their promises?
-
Van de Werf F. Inhibitors of the platelet thrombin receptor. Will they live up to their promises? Circulation 2011; 123: 1833-1835.
-
(2011)
Circulation
, vol.123
, pp. 1833-1835
-
-
Van de Werf, F.1
-
24
-
-
85027946204
-
Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes. The lessons from antagonising the cellular effects of thrombin-acute coronary syndromes trial
-
O'Donoghue M, Bhatt DL, Wiviott SD, et al. Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes. The lessons from antagonising the cellular effects of thrombin-acute coronary syndromes trial. Circulation 2011; 123: 1843-1853.
-
(2011)
Circulation
, vol.123
, pp. 1843-1853
-
-
O'Donoghue, M.1
Bhatt, D.L.2
Wiviott, S.D.3
-
25
-
-
85027951718
-
Randomized trial of atopaxar in the treatment of patients with coronary artery disease. The lessons from antagonising the cellular effect of thrombin-coronary artery disease trial
-
Wiviott SD, Flather MD, O'Donoghue ML, et al. Randomized trial of atopaxar in the treatment of patients with coronary artery disease. The lessons from antagonising the cellular effect of thrombin-coronary artery disease trial. Circulation 2011; 123: 1854-1863.
-
(2011)
Circulation
, vol.123
, pp. 1854-1863
-
-
Wiviott, S.D.1
Flather, M.D.2
O'Donoghue, M.L.3
-
26
-
-
84870937888
-
Risk of intracranial hemorrhage with proteaseactivated receptor-1 antagonists
-
Lee M, Saver JL, Hong KS, et al. Risk of intracranial hemorrhage with proteaseactivated receptor-1 antagonists. Stroke 2012; 43: 3189-3195.
-
(2012)
Stroke
, vol.43
, pp. 3189-3195
-
-
Lee, M.1
Saver, J.L.2
Hong, K.S.3
-
27
-
-
58149156652
-
SCH530348, a novel antiplatelet agent, demonstrated no bleeding risk alone or in combination with aspirin or clopidogrel in cynomolgus monkeys
-
Chintala M, Vemapalli S, Kurowski S, et al. SCH530348, a novel antiplatelet agent, demonstrated no bleeding risk alone or in combination with aspirin or clopidogrel in cynomolgus monkeys. Arterioscler Thromb Vasc Biol 2008; 28: e138-139.
-
(2008)
Arterioscler Thromb Vasc Biol
, vol.28
-
-
Chintala, M.1
Vemapalli, S.2
Kurowski, S.3
-
28
-
-
79952487685
-
The novel and orally active thrombin receptor antagonist E5555 (Atopaxar) inhibits arterial thrombosis without affecting bleeding time in guinea pigs
-
Kogushi M, Matsuoka T, Kawata T, et al. The novel and orally active thrombin receptor antagonist E5555 (Atopaxar) inhibits arterial thrombosis without affecting bleeding time in guinea pigs. Eur J Pharmacol 2011; 657: 131-137.
-
(2011)
Eur J Pharmacol
, vol.657
, pp. 131-137
-
-
Kogushi, M.1
Matsuoka, T.2
Kawata, T.3
-
29
-
-
84863660786
-
Safety and efficacy of targeting platelet proteinase-activated receptors in combination with existing anti-platelet drugs as anti-thrombotics in mice
-
Lee H, Sturgeon SA, Mountford JK, et al. Safety and efficacy of targeting platelet proteinase-activated receptors in combination with existing anti-platelet drugs as anti-thrombotics in mice. Br J Pharmacol 2012; 166: 2188-2197.
-
(2012)
Br J Pharmacol
, vol.166
, pp. 2188-2197
-
-
Lee, H.1
Sturgeon, S.A.2
Mountford, J.K.3
-
30
-
-
16844383611
-
Emergency Administration of Abciximab for Treatment of Patients With Acute Ischaemic Stroke
-
Abciximab Emergent Stroke Treatment Trial (AbE.S.T. T) Investigators
-
Abciximab Emergent Stroke Treatment Trial (AbESTT) Investigators. Emergency Administration of Abciximab for Treatment of Patients With Acute Ischaemic Stroke. Stroke 2005; 36: 880-890.
-
(2005)
Stroke
, vol.36
, pp. 880-890
-
-
-
31
-
-
38149053126
-
Emergency Administration of Abciximab for Treatment of Patients With Acute Ischaemic Stroke: Results of an International Phase III Trial
-
Adams HP, Effron MB, Torner J, et al. Emergency Administration of Abciximab for Treatment of Patients With Acute Ischaemic Stroke: Results of an International Phase III Trial. Stroke 2008; 39: 87-99.
-
(2008)
Stroke
, vol.39
, pp. 87-99
-
-
Adams, H.P.1
Effron, M.B.2
Torner, J.3
-
32
-
-
33746234764
-
Conformation-specific blockade of the integrin GPIIb/IIIa
-
Schwarz M, Meade G, Stoll P. Conformation-specific blockade of the integrin GPIIb/IIIa. Circ Res 2006; 99: 25-33.
-
(2006)
Circ Res
, vol.99
, pp. 25-33
-
-
Schwarz, M.1
Meade, G.2
Stoll, P.3
-
33
-
-
0037132843
-
Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: A meta analysis of all major randomized clinical trials
-
Boersma E, Harrington RA, Moliterno DJ. et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: A meta analysis of all major randomized clinical trials. Lancet 2002; 259: 189-198.
-
(2002)
Lancet
, vol.259
, pp. 189-198
-
-
Boersma, E.1
Harrington, R.A.2
Moliterno, D.J.3
-
35
-
-
77956988100
-
The role of glycoprotein Ibalpha and von Willebrand factor interaction in stroke development
-
Stoll G, Kleinschnitz C, Nieswandt B. The role of glycoprotein Ibalpha and von Willebrand factor interaction in stroke development. Hamostaseologie 2010; 30: 136-138.
-
(2010)
Hamostaseologie
, vol.30
, pp. 136-138
-
-
Stoll, G.1
Kleinschnitz, C.2
Nieswandt, B.3
-
37
-
-
84867088188
-
Next-generation antithrombotics in ischaemic stroke: Preclinical perspective on 'bleeding-free antithrombosis'
-
Kraft P, De Meyer SF, Kleinschnitz C. Next-generation antithrombotics in ischaemic stroke: preclinical perspective on 'bleeding-free antithrombosis'. J Cereb Blood Flow Metab 2012; 32: 1831-1840.
-
(2012)
J Cereb Blood Flow Metab
, vol.32
, pp. 1831-1840
-
-
Kraft, P.1
De Meyer, S.F.2
Kleinschnitz, C.3
-
38
-
-
34249889864
-
The role of von Willebrand factor in thrombus formation
-
Ruggeri ZM. The role of von Willebrand factor in thrombus formation. Thromb Res 2007; 120 (Suppl 1): S5-S9.
-
(2007)
Thromb Res
, vol.120
, Issue.SUPPL. 1
-
-
Ruggeri, Z.M.1
-
39
-
-
0038494921
-
Platelet-collagen interaction: Is GPVI the central receptor?
-
Nieswandt B, Watson SP. Platelet-collagen interaction: is GPVI the central receptor? Blood 2003; 102: 449-461.
-
(2003)
Blood
, vol.102
, pp. 449-461
-
-
Nieswandt, B.1
Watson, S.P.2
-
40
-
-
0037240588
-
A crucial role of glycoprotein VI for platelet recruitment to the injured arterial wall in vivo
-
Massberg S, Gawaz M, Grüner S, et al. A crucial role of glycoprotein VI for platelet recruitment to the injured arterial wall in vivo. J Exp Med 2003; 197: 41-49.
-
(2003)
J Exp Med
, vol.197
, pp. 41-49
-
-
Massberg, S.1
Gawaz, M.2
Grüner, S.3
-
41
-
-
34247643257
-
Targeting Platelets in Acute Experimental Stroke: Impact of Glycoprotein Ib, VI, and IIb/IIIa Blockade on Infarct Size, Functional Outcome, and Intracranial Bleeding
-
Kleinschnitz C, Pozgajova M, Pham M, et al. Targeting Platelets in Acute Experimental Stroke: Impact of Glycoprotein Ib, VI, and IIb/IIIa Blockade on Infarct Size, Functional Outcome, and Intracranial Bleeding. Circulation 2007; 115: 2323-2330.
-
(2007)
Circulation
, vol.115
, pp. 2323-2330
-
-
Kleinschnitz, C.1
Pozgajova, M.2
Pham, M.3
-
42
-
-
65349125946
-
Deficiency of von Willebrand factor protects mice from ischaemic stroke
-
Kleinschnitz C, De Meyer SF, Schwarz T, et al. Deficiency of von Willebrand factor protects mice from ischaemic stroke. Blood 2009; 113: 3600-3603.
-
(2009)
Blood
, vol.113
, pp. 3600-3603
-
-
Kleinschnitz, C.1
De Meyer, S.F.2
Schwarz, T.3
-
43
-
-
0037145037
-
Integrins: Bidirectional, allosteric signaling machines
-
Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell 2002; 110: 673-687.
-
(2002)
Cell
, vol.110
, pp. 673-687
-
-
Hynes, R.O.1
-
44
-
-
7044233073
-
Platelet physiology and thrombosis
-
Andrews RK, Berndt MC. Platelet physiology and thrombosis. Thromb Res 2004; 114: 447-453.
-
(2004)
Thromb Res
, vol.114
, pp. 447-453
-
-
Andrews, R.K.1
Berndt, M.C.2
-
45
-
-
4444354602
-
A humanized monoclonal antibody against vWF A1 domain inhibits vWF: RiCof activity and platelet adhesion in human volunteers
-
abstract OC328
-
Machin SJ, Clarke C, Ikemura O, et al. A humanized monoclonal antibody against vWF A1 domain inhibits vWF: RiCof activity and platelet adhesion in human volunteers. J Thromb Haemost 2003; 1: Abstract OC328.
-
(2003)
J Thromb Haemost
, vol.1
-
-
Machin, S.J.1
Clarke, C.2
Ikemura, O.3
-
46
-
-
37349040378
-
First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers
-
Gilbert JC, DeFeo-Fraulini T, Hutabarat RM, et al. First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers. Circulation 2007; 116: 2678-2686.
-
(2007)
Circulation
, vol.116
, pp. 2678-2686
-
-
Gilbert, J.C.1
DeFeo-Fraulini, T.2
Hutabarat, R.M.3
-
47
-
-
79961210182
-
The von Willebrand Inhibitor ARC1779 Reduces Cerebral Embolisation After Carotid Endarterectomy: A Randomized Trial
-
Markus HS, McCollum C, Imray C, et al. The von Willebrand Inhibitor ARC1779 Reduces Cerebral Embolisation After Carotid Endarterectomy: A Randomized Trial. Stroke 2011; 42: 2149-2153.
-
(2011)
Stroke
, vol.42
, pp. 2149-2153
-
-
Markus, H.S.1
McCollum, C.2
Imray, C.3
-
48
-
-
79960058122
-
Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared to currently marketed antiplatelet drugs
-
Ulrichts H, Silence K, Schoolmeester A, et al. Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared to currently marketed antiplatelet drugs. Blood 2011; 118: 757-765.
-
(2011)
Blood
, vol.118
, pp. 757-765
-
-
Ulrichts, H.1
Silence, K.2
Schoolmeester, A.3
-
49
-
-
84872657985
-
Safety, tolerability, pharmacokinetics and pharmacodynamics of anti-vWF nanobody ALX-0681 after single and multiple subcutaneous administrations to healthy volunteers
-
abstract 1063
-
Abd-Elaziz K, Kamphuisen PW, Lyssens C, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of anti-vWF nanobody ALX-0681 after single and multiple subcutaneous administrations to healthy volunteers. Blood 2009; 114: Abstract 1063.
-
(2009)
Blood
, vol.114
-
-
Abd-Elaziz, K.1
Kamphuisen, P.W.2
Lyssens, C.3
-
50
-
-
79960071636
-
The in vitro effect of the new antithrombotic drug candidate ALX-0081 on blood samples of patients undergoing percutaneous coronary intervention
-
van Loon JE, de Jaegere PP, Ulrichts H, et al. The in vitro effect of the new antithrombotic drug candidate ALX-0081 on blood samples of patients undergoing percutaneous coronary intervention. Thromb Haemost 2011; 106: 165-171.
-
(2011)
Thromb Haemost
, vol.106
, pp. 165-171
-
-
van Loon, J.E.1
de Jaegere, P.P.2
Ulrichts, H.3
-
51
-
-
0035910757
-
Long-term antithrombotic protection by in vivo depletion of platelet glycoprotein VI in mice
-
Nieswandt B, Schulte V, Bergmeier W, et al. Long-term antithrombotic protection by in vivo depletion of platelet glycoprotein VI in mice. J Exp Med 2001; 193: 459-469.
-
(2001)
J Exp Med
, vol.193
, pp. 459-469
-
-
Nieswandt, B.1
Schulte, V.2
Bergmeier, W.3
-
52
-
-
33745939987
-
Two-phase antithrombotic protection after anti-glycoprotein VI treatment in mice
-
Schulte V, Reusch HP, Pozgajova M, et al. Two-phase antithrombotic protection after anti-glycoprotein VI treatment in mice. Arterioscler Thromb Vasc Biol 2006; 26: 1640-1647.
-
(2006)
Arterioscler Thromb Vasc Biol
, vol.26
, pp. 1640-1647
-
-
Schulte, V.1
Reusch, H.P.2
Pozgajova, M.3
-
53
-
-
13544270777
-
Relative antithrombotic effect of soluble GPVI dimer compared with anti-GPVI antibodies in mice
-
Grüner S, Prostredna M, Koch M, et al. Relative antithrombotic effect of soluble GPVI dimer compared with anti-GPVI antibodies in mice. Blood 2005; 105: 1492-1499.
-
(2005)
Blood
, vol.105
, pp. 1492-1499
-
-
Grüner, S.1
Prostredna, M.2
Koch, M.3
-
54
-
-
84858687801
-
A humanized glycoprotein VI (GPVI) mouse model to asses the antithrombotic efficacies of anti-GPVI agents
-
Mangin PH, Tang CJ, Bourdon C, et al. A humanized glycoprotein VI (GPVI) mouse model to asses the antithrombotic efficacies of anti-GPVI agents. J Pharm Exp Ther 2012; 341: 156-163.
-
(2012)
J Pharm Exp Ther
, vol.341
, pp. 156-163
-
-
Mangin, P.H.1
Tang, C.J.2
Bourdon, C.3
-
55
-
-
1442290149
-
Soluble glycoprotein VI dimer inhibits platelet adhesion and aggregation to the injured vessel wall in vivo
-
Massberg S, Konrad I, Bültmann A, et al. Soluble glycoprotein VI dimer inhibits platelet adhesion and aggregation to the injured vessel wall in vivo. FASEB J 2004; 18: 397-399.
-
(2004)
FASEB J
, vol.18
, pp. 397-399
-
-
Massberg, S.1
Konrad, I.2
Bültmann, A.3
-
56
-
-
77955276576
-
Impact of glycoprotein VI and platelet adhesion on atherosclerosis-a possible role of fibronectin
-
Bültmann A, Li Z, Wagner S, et al. Impact of glycoprotein VI and platelet adhesion on atherosclerosis-a possible role of fibronectin. J Mol Cell Cardiol 2010; 49: 532-542.
-
(2010)
J Mol Cell Cardiol
, vol.49
, pp. 532-542
-
-
Bültmann, A.1
Li, Z.2
Wagner, S.3
-
57
-
-
51749083546
-
The immunoadhesin glycoprotein VI-Fc regulates arterial remodeling after mechanical injury in ApoE-/-mice
-
Schönberger T, Siegel-Axel D, Bussl R, et al. The immunoadhesin glycoprotein VI-Fc regulates arterial remodeling after mechanical injury in ApoE-/-mice. Cardiovasc Res 2008; 80: 131-137.
-
(2008)
Cardiovasc Res
, vol.80
, pp. 131-137
-
-
Schönberger, T.1
Siegel-Axel, D.2
Bussl, R.3
-
58
-
-
84880753729
-
The GPVI-Fc fusion protein Revacept improves cerebral infarct volume and functional outcome in stroke
-
Göbel S, Li ZM, Vogelmann J, et al. The GPVI-Fc fusion protein Revacept improves cerebral infarct volume and functional outcome in stroke. PLOS ONE 2013; 8: e66960.
-
(2013)
PLOS ONE
, vol.8
-
-
Göbel, S.1
Li, Z.M.2
Vogelmann, J.3
-
59
-
-
46149119865
-
Platelet GPVI binds to collagenous structures in the core region of human atheromatous plaque and is critical for atheroprogression in vivo
-
Schulz C, Penz C, Hoffmann C, et al. Platelet GPVI binds to collagenous structures in the core region of human atheromatous plaque and is critical for atheroprogression in vivo. Basic Res Cardiol 2008; 103: 356-367.
-
(2008)
Basic Res Cardiol
, vol.103
, pp. 356-367
-
-
Schulz, C.1
Penz, C.2
Hoffmann, C.3
-
60
-
-
84881540134
-
The GPVI-Fc fusion protein Revacept reduces thrombus formation and improves vascular dysfunction in atherosclerosis without any impact on bleeding times
-
Ungerer M, Li Z, Baumgartner C, et al. The GPVI-Fc fusion protein Revacept reduces thrombus formation and improves vascular dysfunction in atherosclerosis without any impact on bleeding times. PLOS ONE 2013; 8: e71193.
-
(2013)
PLOS ONE
, vol.8
-
-
Ungerer, M.1
Li, Z.2
Baumgartner, C.3
-
61
-
-
8144222110
-
Anti-glycoprotein VI treatment severely compromises hemostasis in mice with reduced alpha2beta1 levels or concomitant aspirin therapy
-
Grüner S, Prostredna M, Aktas B, et al. Anti-glycoprotein VI treatment severely compromises hemostasis in mice with reduced alpha2beta1 levels or concomitant aspirin therapy. Circulation 2004; 110: 2964-2975.
-
(2004)
Circulation
, vol.110
, pp. 2964-2975
-
-
Grüner, S.1
Prostredna, M.2
Aktas, B.3
-
62
-
-
85027958733
-
Novel Antiplatelet Drug Revacept (Dimeric Glycoprotein VI-Fc) Specifically and Efficiently Inhibited Collagen-Induced Platelet Aggre-gation Without Affecting General Hemostasis in Humans
-
Ungerer M, Rosport K, Bültmann A, et al. Novel Antiplatelet Drug Revacept (Dimeric Glycoprotein VI-Fc) Specifically and Efficiently Inhibited Collagen-Induced Platelet Aggre-gation Without Affecting General Hemostasis in Humans. Circulation 2011; 123: 1891-1899.
-
(2011)
Circulation
, vol.123
, pp. 1891-1899
-
-
Ungerer, M.1
Rosport, K.2
Bültmann, A.3
-
63
-
-
0037630017
-
Single injection of P-selectin or P-selectin glycoprotein ligand-1 monoclonal antibody blocks neointima formation after arterial injury in Apo E deficient mice
-
Philips JW, Barringhaus KG, Sanders JM, et al. Single injection of P-selectin or P-selectin glycoprotein ligand-1 monoclonal antibody blocks neointima formation after arterial injury in Apo E deficient mice. Circulation 2003; 107: 2244-2249.
-
(2003)
Circulation
, vol.107
, pp. 2244-2249
-
-
Philips, J.W.1
Barringhaus, K.G.2
Sanders, J.M.3
-
64
-
-
84876779047
-
Effects of the p selectin antagonist inclacumab on myocardial damage after percutaneous coronary intervention for non-ST-segment elevation myocardial infarction. The SELECT-ACS trial
-
Tardif JC, Tanguay JF, Wright SS, et al. Effects of the p selectin antagonist inclacumab on myocardial damage after percutaneous coronary intervention for non-ST-segment elevation myocardial infarction. The SELECT-ACS trial. J Am Coll Cardiol 2013; 61: 2048-2055.
-
(2013)
J Am Coll Cardiol
, vol.61
, pp. 2048-2055
-
-
Tardif, J.C.1
Tanguay, J.F.2
Wright, S.S.3
-
65
-
-
84874256510
-
Historical lessons in translational medicine: Cyclooxygenase inhibition and P2Y12 antagonism
-
Fitzgerald DJ, FitzGerald GA. Historical lessons in translational medicine: Cyclooxygenase inhibition and P2Y12 antagonism. Circ Res 2013; 112: 174-194.
-
(2013)
Circ Res
, vol.112
, pp. 174-194
-
-
Fitzgerald, D.J.1
FitzGerald, G.A.2
-
66
-
-
18244394040
-
Antithrombotic Properties of the Thromboxane A2/Prostaglandin H2 Receptor Antagonist S18886 on Prevention of Platelet-Dependent Cyclic Flow Reductions in Dogs
-
Maalej N, Osman HE, Shanmuganayagam D, et al. Antithrombotic Properties of the Thromboxane A2/Prostaglandin H2 Receptor Antagonist S18886 on Prevention of Platelet-Dependent Cyclic Flow Reductions in Dogs. J Cardiovasc Pharmacol 2005; 45: 389-395.
-
(2005)
J Cardiovasc Pharmacol
, vol.45
, pp. 389-395
-
-
Maalej, N.1
Osman, H.E.2
Shanmuganayagam, D.3
-
67
-
-
79958770159
-
Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): A randomised, double-blind, parallel-group trial
-
on behalf of the PERFORM Study Investigators
-
Bousser MG, Amarenco P, Chamorro A, et al., on behalf of the PERFORM Study Investigators. Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial. Lancet 2011; 377: 2013-2022.
-
(2011)
Lancet
, vol.377
, pp. 2013-2022
-
-
Bousser, M.G.1
Amarenco, P.2
Chamorro, A.3
-
68
-
-
84877128891
-
Single ascending oral dose pharmacokinetics and pharmacodynamics study of EV-077: The specific inhibitor of prostanoid-and isoprostane-induced cellular activation
-
Richardson A, Sakariassen KS, Meyer JP, et al. Single ascending oral dose pharmacokinetics and pharmacodynamics study of EV-077: the specific inhibitor of prostanoid-and isoprostane-induced cellular activation. Eur J Clin Pharmacol 2013; 69: 459-465.
-
(2013)
Eur J Clin Pharmacol
, vol.69
, pp. 459-465
-
-
Richardson, A.1
Sakariassen, K.S.2
Meyer, J.P.3
-
69
-
-
74749106019
-
Targeted inhibition of the serotonin 5HT2A receptor improves coronary patency in an in vivo model of recurrent thrombosis
-
Przyklenk K, Frelinger III AL, Linden MD, et al. Targeted inhibition of the serotonin 5HT2A receptor improves coronary patency in an in vivo model of recurrent thrombosis. J Thromb Haemost 2012; 8: 331-340.
-
(2012)
J Thromb Haemost
, vol.8
, pp. 331-340
-
-
Przyklenk, K.1
Frelinger III, A.L.2
Linden, M.D.3
-
70
-
-
84865224181
-
Why and how to eliminate spontaneous platelet aggregation in blood measured by multiple electrode aggregometry
-
Bampalis VG, Brantl SA, Siess W. Why and how to eliminate spontaneous platelet aggregation in blood measured by multiple electrode aggregometry. J Thromb Haemost 2012; 10: 1710-1714.
-
(2012)
J Thromb Haemost
, vol.10
, pp. 1710-1714
-
-
Bampalis, V.G.1
Brantl, S.A.2
Siess, W.3
-
71
-
-
77956884231
-
Cilostazol for prevention of secondary stroke (CSPS"): An aspirin-controlled, double-blind, randomised noninferiority trial
-
Shinohara Y, Katayama Y, Uchiyama S, et al. Cilostazol for prevention of secondary stroke (CSPS"): an aspirin-controlled, double-blind, randomised noninferiority trial. Lancet Neurology 2010; 9: 959-968.
-
(2010)
Lancet Neurology
, vol.9
, pp. 959-968
-
-
Shinohara, Y.1
Katayama, Y.2
Uchiyama, S.3
-
72
-
-
34248352504
-
Aspirin dose for the prevention of cardiovascular disease: A systematic review
-
Campbell CL, Smyth S, Montalescot G, et al. Aspirin dose for the prevention of cardiovascular disease: a systematic review. J Am Med Assoc 2007; 297: 2018-2024.
-
(2007)
J Am Med Assoc
, vol.297
, pp. 2018-2024
-
-
Campbell, C.L.1
Smyth, S.2
Montalescot, G.3
-
73
-
-
3242770664
-
Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): Randomised, double-blind, placebo-controlled trial
-
Diener HC, Bogousslavsky J, Blass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004; 364: 331-337.
-
(2004)
Lancet
, vol.364
, pp. 331-337
-
-
Diener, H.C.1
Bogousslavsky, J.2
Blass, L.M.3
-
74
-
-
84865485153
-
Effects of clopidogrel added to aspirin in patients with recent lacunar stroke
-
The SP3 investigators
-
The SP3 investigators. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. N Engl J Med 2012; 367: 817-825.
-
(2012)
N Engl J Med
, vol.367
, pp. 817-825
-
-
|